Leif Bring
Leif BringChairman of the Board
Since 2005

Education
MSc from Chalmers Technical University, Gothenburg, and studies in Economy & Finance at Mälardalen University, Sweden

Other assignments
CEO of the Intercedo Group and Executive Director at Dizlin Pharmaceuticals AB

Experience and prior assignments
More than 35 years of experience in corporate development and executive management. He has also been a Board member of Transientic Interactions AB and Chairman of the Board of Robust Ståldörrar. Leif Bring has broad experience from international business and was based in Atlanta, where he held the position as Director Business Development at ABB Flakt Inc. He has worked several years with corporate development in a joint project with the ABB Group and Boston Consulting Group. He has also been Regional Manager, Middle East for the ABB Group as well as CEO of Dizlin Pharmaceuticals AB, 2005-2019. He is one of the founders of Dizlin Pharmaceuticals AB.

Elias Eriksson
Elias Eriksson Board member
Since 2018

Education
Medical Doctor and Professor of Pharmacology at the Department of Physiology and Neuroscience, Sahlgrenska Academy, University of Gothenburg, Sweden

Other assignments
Chief Medical Officer at Dizlin Pharmaceuticals AB since 2013

Experience and prior assignments
Active in preclinical and clinical neuropsychopharmacological research for four decades, written approximately 300 scientific papers within these fields, and supervised 20 PhD students. Has been a member of the Scientific Council for Medicine and Health at the Swedish Research Council and is currently a Board member and the Secretary of the International College of Neuropsychopharmacology (CINP).

Åsa Hansdotter
Åsa HansdotterBoard member
Since 2020

Education
Master of Laws from Lund University, Sweden

Other assignments
Partner of the business law firm HWF Advokater AB in Helsingborg. Board member of Proventus Capital Management AB

Experience and prior assignments
Previously a partner of Mannheimer Swartling Advokatbyrå where she was active since 2001, whereby 2009–2011 in Russia, before co-founding HWF in 2018. She operates within public and private M&A, equity capital markets law and corporate commercial matters for listed and non-listed companies. Industry sectors include chemicals, health care and life sciences and industrials.

Johan von Heijne
Johan von Heijne Board member
Since 2020

Education
BSc in molecular biology and an MBA in international marketing, Uppsala University

Other assignments
CEO for Pharm Assist Sweden AB

Experience and prior assignments
More than 35 years of experience from the life science, pharmaceutical, and medical device industries as well as the financial industry. He has served as CEO and Board member of AroCell AB (NASDAQ), CEO of Biolin Scientific AB (Ratos AB), CEO of Healthcore AB, COO of Radi Medical AB (today St Jude), General Manager and Executive at GE Healthcare, VP Pharmacia Biotech AB (today Pfizer and Danaher) and Director Corporate Finance at Enskilda Securities AB (today SEB).

Nil Dizdar Segrell
Nil Dizdar Segrell Board member
Since 2003

Education
MD, Linköping University (1989), Specialist in Neurology (1993), Specialist in Clinical Chemistry (1999), PhD, Linköping University (1999), Associate professor, Linköping University (2012), Sweden

Other assignments
Since 2002, member of the Steering Board of the Swedish Movement Disorder Society, SWEMODIS, affiliated to the International Parkinson and Movement Disorder Society, MDS. Founding member of the Scandinavian Movement Disorder Society, Scandmodis. Since 2009, she is also member (and founding member) of the steering board of the Swedish National Network for Parkinson Research, SWEPAR-Net

Experience and prior assignments
More than 25 years of experience from Neurology. She is also specialist in Clinical Chemistry and started her research on Malignant melanoma and later on Parkinson’s disease. The knowledge from both these fields led to the development of the first Infudopa™ formulation for intravenous use. She is one of the founders of Dizlin Pharmaceuticals AB.

Staffan Schüberg
Staffan Schüberg Board member
Since 2016

Education
BA Hons Business Administration from the London Guildhall University, United Kingdom

Other assignments
CEO and Member of the Board of Directors of the ESTEVE Group. Member of the Board of Directors of Swedish Orphan Biovitrum AB (SOBI), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Corporacíon Químico Farmacéutical Esteve S.A.

Experience and prior assignments
More than 20 years of experience from board and executive management roles, including a number of senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the U.S. Operations and Global Chief Commercial Officer on Group level.

Anders Stenström
Anders Stenström Board member
Since 2014

Education
MBA from School of Business, Economics and Law at University of Gothenburg, Sweden

Other assignments
Managing Director of CampusPharma AB

Experience and prior assignments
More than 25 years of experience from the pharmaceutical industry. Since 2004, he is the co-founder, co-owner and Managing Director of CampusPharma AB.

Anders Tullgren
Anders TullgrenBoard member
Since 2020

Education
MSc in Pharmacy from Uppsala University, Sweden

Other assignments
Board member of Branding Science Ltd, UK and Farmalisto, Colombia, and Chairman of the Board for Xbrane Biopharma AB, Sweden

Experience and prior assignments
More than 35 years of global experience in the pharmaceutical industry, and he has had senior leadership roles in the United States, Germany, France, the United Kingdom as well as the Nordic region. The latest role, which he left in 2017, was as President of the Intercontinental region of Bristol Myers Squibb.